What’s New and Updates/Changes:

This version of the Guidance has been updated to reflect several important developments, including the recent approval of elbasvir/grazoprevir, together with new information regarding the use of testing for HCV resistance associated variants.

Updated recommendations reflecting this approval are provided in these sections:

Other updates reflecting recent data are provided in:

Updated recommendations regarding the monitoring of cirrhotic patients are also provided in:

Drug-drug interaction updates are also provided, particularly as they relate to antiretroviral agents and calcineurin inhibitors in:

Updated references have been provided throughout the Guidance.